Wake up ON

Contera Pharma is developing CP-012, an investigational bedtime tablet designed to release levodopa before waking, to address early morning OFF in Parkinson's disease.

Who we are

Contera Pharma is a Danish clinical-stage biopharmaceutical company based in Hørsholm, Denmark. We are focused on addressing one of the most common and burdensome challenges in Parkinson's disease: the difficult hours of the early morning.

Our sole focus is CP-012, an investigational, delayed-release, dual-pulse levodopa/carbidopa tablet taken at bedtime. CP-012 combines a well-established Parkinson's therapy with an innovative drug-delivery technology, designed to deliver levodopa in the early morning hours, before patients wake up.

Our team brings together decades of experience in Parkinson's disease, clinical drug development and business development from leading pharmaceutical companies, including H. Lundbeck, Novo and LEO Pharma.

Teaser image

The problem

The hardest part of the day starts before it begins.

For many people living with Parkinson's disease, the effects of medication wear off overnight. They may wake up stiff, slow and struggling to get out of bed until their first morning dose takes effect a condition known as morning OFF.

Despite available treatments, morning OFF remains a significant and inadequately addressed challenge in Parkinson's care.

Teaser image

Our solution

A better morning begins at bedtime.

CP-012 is an investigational levodopa/carbidopa tablet taken at bedtime alongside the patient's existing Parkinson's medication. Using a proprietary tablet-in-tablet design, CP-012 is designed to delay the release of levodopa until the early morning hours, with the aim of providing therapeutic drug levels before waking.

Teaser image

"With CP-012, we are working to change when levodopa works, not what it is, so that people with Parkinson’s can start their day without waiting for their medication to take effect.”

Anne Birk Østerskov,
Chief Medical Officer

Why CP-012

Significant unmet medical need
Morning OFF and nocturnal immobility are common and burdensome complications of Parkinson's disease, with existing treatment options leaving important needs unaddressed.

Established active ingredients
CP-012 combines levodopa/carbidopa, the gold-standard treatment for Parkinson's motor symptoms, with an innovative delayed-release formulation.

Clinical proof of intended drug release profile
Phase 1 studies in healthy volunteers and people with Parkinson’s confirmed delayed levodopa absorption into the early morning hours.

Simple oral administration
A bedtime tablet designed to complement existing treatment

Experienced development team
A focused team with extensive experience in Parkinson's disease, clinical development and pharmaceutical partnering.

Teaser image

Interested in partnering or investing?

We are actively seeking partners and investors to bring CP-012 to patients.

Teaser image